Bristol-Myers suspends hepatitis C treatment study, cites possible cardiac concern
bljohnston said
Aug 24, 2012
As i am told by study doctors 10 subjects including myself have developed various heart issues due to the study drug inx-189. I developed dilated cardiomyopathy, which is a weakening and thinning of the heart muscle. I was on the highest dose of inx-189 of 200mg. Scary thing is, the first patient who developed acute cardiomyopathy was also on this dose! Multiple 2d echocardiograms and a cardiac MRI are tracking my heart. Thankfully all visits are paid for.
-- Edited by bljohnston on Saturday 25th of August 2012 04:54:18 PM
Drugmaker Bristol-Myers Squibb Co. is suspending a midstage study of a potential hepatitis C treatment after at least one patient suffered heart failure.
The New York company hasn't determined the cause or whether it is tied to the potential treatment, so it is examining all patients who took the drug.
As i am told by study doctors 10 subjects including myself have developed various heart issues due to the study drug inx-189. I developed dilated cardiomyopathy, which is a weakening and thinning of the heart muscle. I was on the highest dose of inx-189 of 200mg. Scary thing is, the first patient who developed acute cardiomyopathy was also on this dose! Multiple 2d echocardiograms and a cardiac MRI are tracking my heart. Thankfully all visits are paid for.
-- Edited by bljohnston on Saturday 25th of August 2012 04:54:18 PM
http://www.startribune.com/lifestyle/health/164724656.html?refer=y%22,,0,0,,,,&refer=y
Drugmaker Bristol-Myers Squibb Co. is suspending a midstage study of a potential hepatitis C treatment after at least one patient suffered heart failure.
The New York company hasn't determined the cause or whether it is tied to the potential treatment, so it is examining all patients who took the drug.